13F reference period
Q2 2026
Security Snapshot
Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA) Institutional Ownership
CUSIP: 114082308
13F Institutional Holders and Ownership History from Q2 2025 to Q2 2026
Institutions Reporting
0
Shares (Excl. Options)
0
Price
$0.20
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.005 per share
- Symbol
- ERNA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 0
- Total 13F value
- $0
- Share change
- -3,574,348
- Value change
- -$711,398
- Number of holders
- 0
- Shares outstanding
- 1,216,283
- SEC-reported price per share
- $0.20
- Insider filing price
- $0.20
Latest holder snapshot
4 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- ERNA - Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share is tracked under CUSIP 114082308.
- 0 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 19 to 0 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to $0.
$711.4K
Full value: $711,400 · USD · 31 Mar 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 0 institutions filings for Q2 2026.
Security key
114082308
13F reference period
Q2 2026
13F holders
0
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
ERNA full holder history
Ernexa Therapeutics Inc. SEC filings
Ernexa Therapeutics Inc. company facts
Ernexa Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 114082308:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
ERNA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Cherington Charles | 35% | $12,949,602 | 10,791,335 | Charles Cherington | 10 Feb 2026 | |||
| Konar Shameek | 7.1% | $720,505 | 558,531 | Shameek Konar | 30 Jun 2025 | |||
| IAF, LLC | 4.1% | $584,191 | 315,779 | IAF, LLC | 28 Jul 2025 | |||
| Freebird Partners LP | 9.9% | 0% | $24,082 | -$133,126 | 120,412 | -85% | Freebird Partners LP | 10 Feb 2026 |
| HALPERN JOHN D | 5.6% | $13,350 | 66,751 | John D. Halpern | 10 Feb 2026 |
As of 30 Jun 2026,
0
institutional investors reported holding
0
shares of
Ernexa Therapeutics Inc. - Common Stock, par value $0.005 per share (ERNA).
This represents
0%
of the company’s total
outstanding shares.
1.22M
Full value: 1,216,283 · shares · Stored outstanding share countQuarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Headline period
Q2 2026
Rows shown
1-5 of 5